Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

Background: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical and biochemical response induced by originator af...

Full description

Bibliographic Details
Main Authors:	Davide Massimi, Brigida Barberio, Lorenzo Bertani, Francesco Costa, Antonio Ferronato, Sonia Facchin, Romilda Cardin, Linda Cingolani, Cesare Casadei, Renata D’Incà, Fabiana Zingone, Edoardo Vincenzo Savarino
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-06-01
Series:	Therapeutic Advances in Gastroenterology
Online Access:	https://doi.org/10.1177/17562848211023384

Similar Items

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
by: Linda Cingolani, et al.
Published: (2021-05-01)

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study
by: Brigida Barberio, et al.
Published: (2021-07-01)

Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
by: Sonia Facchin, et al.
Published: (2021-03-01)

Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital
by: Brigida Barberio, et al.
Published: (2020-07-01)

A Survey on Nutritional Knowledge in Coeliac Disease Compared to Inflammatory Bowel Diseases Patients and Healthy Subjects
by: Ilaria Marsilio, et al.
Published: (2020-04-01)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
by: Reem Kashlan, MPH, et al.
Published: (2021-02-01)

Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study
by: Zingone, Fabiana, et al.
Published: (2020-11-01)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
by: Subedi S, et al.
Published: (2019-07-01)

Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
by: Sarah Fischer, et al.
Published: (2021-01-01)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
by: Ágnes Milassin, et al.
Published: (2019-04-01)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
by: Fitzgerald T, et al.
Published: (2021-01-01)

Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases
by: Joanna Sieczkowska, et al.
Published: (2016-09-01)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
by: Bas JM Peters, et al.
Published: (2021-02-01)

Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis
by: Hanrahan, C., et al.
Published: (2021)

Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients
by: Jørgen Jahnsen
Published: (2016-05-01)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
by: María Fernanda Guerra Veloz, et al.
Published: (2019-06-01)

Response to Infliximab Biosimilar in a Case of Reactive Arthritis: Our Experience
by: Amruta Deepak Morey, et al.
Published: (2019-12-01)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
by: Fabiana Zingone, et al.
Published: (2020-07-01)

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
by: Viktoria Bergqvist, et al.
Published: (2018-10-01)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
by: Evelien Moorkens, et al.
Published: (2020-10-01)

Economic impact of biosimilar drugs in Italy: past, present and future of infliximab and etanercept
by: Andrea Marcellusi, et al.
Published: (2017-07-01)

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
by: Yazici Y, et al.
Published: (2018-10-01)

Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients
by: Carla Marinelli, et al.
Published: (2019-01-01)

Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
by: Anna Pękala, et al.
Published: (2021-06-01)

The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
by: Olga Barszczewska, et al.
Published: (2021-06-01)

The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
by: Rossella Talotta, et al.
Published: (2017-10-01)

The impact of biosimilar on health care expenditure in Germany, the United States and Taiwan: A case study for Infliximab biosimilar (Remsima®,Inflectra®,Flixabi® and Renflexis®)
by: Ching-Hsiu Chen, et al.
Published: (2018)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
by: Tomoo Nakagawa, et al.
Published: (2019-10-01)

A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population
by: Yazici Y, et al.
Published: (2018-10-01)

Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database
by: Matsumoto T, et al.
Published: (2021-02-01)

Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success
by: Brigida Barberio, et al.
Published: (2020-08-01)

SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience
by: Shing T. Law, et al.
Published: (2019-01-01)

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
by: D J Buurman, et al.
Published: (2018-01-01)

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
by: Yujeong Kim, et al.
Published: (2020-07-01)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
by: Magdalena Kaniewska, et al.
Published: (2020-11-01)

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
by: Catherine Beauvais, et al.
Published: (2021-04-01)

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
by: Kerry Mansell, et al.
Published: (2019-11-01)

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
by: Mark C. Genovese, et al.
Published: (2020-03-01)

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany
by: Waller J, et al.
Published: (2017-03-01)

Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
by: An Q, et al.
Published: (2019-03-01)